Pre-made Erenumab benchmark antibody ( Whole mAb, anti-CALCRL/CGRPR therapeutic antibody, Anti-CRLR/LMPHM8 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Erenumab biosimilar, Whole mAb, Anti-CALCRL/CGRPR Antibody: Anti-CRLR/LMPHM8 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Erenumab, sold under the brand name Aimovig, is a medication which targets the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-193-1mg	1mg	3090	30%	2163

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Erenumab biosimilar, Whole mAb, Anti-CALCRL/CGRPR Antibody: Anti-CRLR/LMPHM8 therapeutic antibody
INN Name	Erenumab
Target	CGRPR
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	NFD
100% SI Structure	6umh:HL/6umi:HL/6umj:HL
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2016
Year Recommended	2017
Companies	Amgen;Novartis
Conditions Approved	Migraine
Conditions Active	na
Conditions Discontinued	Hot flushes
Development Tech	Abgenix XenoMouse